Tag: vTV Therapeutics


vTV Therapeutics Inc. (NASDAQ: VTVT) Jumps 7% Following Licensing Agreement With Cantex Pharmaceuticals for Azaliragon

vTV Therapeutics Inc. (NASDAQ: VTVT) jumped 6.78% after announcing the signing of a licensing agreement with Cantex Pharmaceuticals. According to the agreement, Cantex has received exclusive global rights for the development and commercialization of vTV’s antagonist of RAGE, azeliragon.¬† Cantex to develop and commercialize azeliragon globally¬† Cantex CEO and President […]